Clinical Trials Logo

Clinical Trial Summary

West Nile virus (WNV) is considered an emerging virus in the United States, and infection can lead to severe illness in older adults. This study will evaluate the safety of and immune response to a live West Nile virus vaccine (WN/DEN4Δ30) for the prevention of West Nile encephalitis in adults 50 to 65 years old.


Clinical Trial Description

WNV is the leading vector-borne cause of viral encephalitis in the United States. Severe illness is most common in older adults, and in this population, the virus can cause hepatitis, meningitis, and encephalitis leading to paralysis, coma, and death. WNV illness is a public health issue and is an emerging disease in the United States. This study will evaluate the safety and immunogenicity of a live attenuated West Nile/dengue chimeric virus vaccine (WN/DEN4Δ30) for the prevention of West Nile encephalitis in adults 50 to 65 years old.

This study will enroll healthy adults, 50 to 65 years old, who have no history of previous flavivirus infection. Participants will be randomly assigned to receive the WN/DEN4Δ30 vaccine or placebo vaccine at study entry (Day 0). At the entry visit, participants will undergo a medical history review, physical examination, blood collection, and vital sign measurements; female participants will also take a pregnancy test. Participants will then receive their assigned vaccine, and they will remain in the clinic for 30 minutes after the vaccination for monitoring. Participants will record their temperature and symptoms 3 times a day for 16 days after each vaccination. Additional study visits will occur on Days 3, 6, 8, 10, 12, 14, 16, 21, 28, 56, 90, and 150. These visits may include the same study procedures that occurred at the entry visit. At a study visit on Day 180, participants will receive another dose of their assigned vaccine. Additional study visits will occur on Days 183, 186, 188, 190, 192, 194, 196, 201, 208, 236, 270, and 360. All study procedures after the second vaccination will be the same that occurred after the first vaccination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02186626
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Completed
Phase Phase 1
Start date February 2014
Completion date July 2016

See also
  Status Clinical Trial Phase
Completed NCT00069316 - Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00138463 - West Nile Virus Natural History N/A
Completed NCT00068055 - IVIG - West Nile Encephalitis: Safety and Efficacy Phase 1/Phase 2
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Withdrawn NCT04371003 - Prospective Investigation of Oxidative Stress in West Nile Virus Infection
Completed NCT00387283 - Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 Phase 1
Completed NCT05294003 - West Nile Virus Seroprevalence Under Bird Ringers
Completed NCT00515385 - A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults Phase 1